Drug Discovery Featured Articles & Applications

1. How Sethera Harnesses A Promiscuous Enzyme To Make Recombinant Peptides 10/21/2025

   A class of enzymes previously believed to be specific and intolerant of change might actually have broad applicability.

2. Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development 10/21/2025

   Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.

3. The 9 Fastest-Growing Outsourcing Segments 10/21/2025

   Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

4. 100% U.S. Drug Tariffs: Implications For Pharma And Outsourcing 10/17/2025

   Research Manager Mathini Ilancheran explores the effects of U.S. drug tariffs on global supply chains, multinational pharma firms, and critical partners across drug development.

5. Why Drug Discovery Needs Epistemological Wrapping For Generative AI 10/14/2025

   AI in drug discovery can lead to faster decision cycles, reduced experimental burden, and more hypotheses tested per dollar spent. However, speed without rigor can be catastrophic.

6. Discovery On Hold: How Shutdowns Stall Science And Shake Trust 10/10/2025

   When the federal government shuts down and appropriations lapse, the ripple effects reach deep into early drug development efforts. FDA slows regulatory intake, NIH freezes grant reviews and awards, clinical trials are disrupted, and talent pipelines tighten as student and work visas remain in limbo.

7. Beyond The AI Scientist: Building Defensible Value With Self-Driving Labs 10/9/2025

   Imagine a lab that never sleeps. Work that once consumed months is compressed into a long weekend. That’s the promise of self-driving labs.

8. De-Risking U.S. Market Entry Of Early-Stage Therapeutics 10/8/2025

   One of the most effective ways to de-risk a therapeutic program is to enter preclinical development with a regulatory mindset and a strategic, data-driven approach.

9. Answering The Call To Develop Novel Drugs For Rare Diseases 10/6/2025

   Standing out in the drug development crowd requires entrepreneurial thinking, accelerating innovation, financial considerations, and a commitment to science.

10. CMC For Long-Acting Injectables For TB 10/3/2025

    Long-acting injectables are a potential treatment alternative for tuberculosis, but they require key development considerations from a chemistry, manufacturing, and controls perspective.